Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008
Authors:
Keunchil Park
Joshua K. Sabari
Eric B. Haura
Catherine A. Shu
Alexander I. Spira
Ravi Salgia
Karen L. Reckamp
Rachel E. Sanborn
Ramaswamy Govindan
Joshua Bauml
Joshua C. Curtin
John Xie
Amy Roshak
Patricia Lorenzini
Dawn Millington
Meena Thayu
Roland Knoblauch
Byoung Chul Cho
Affiliated Authors:
Catherine A. Shu
Subjects:
Antibodies, Bispecific (MeSH)
Carcinoma, Non-Small-Cell Lung (MeSH)
Drug-Related Side Effects and Adverse Reactions (MeSH)
Immune System Diseases (MeSH)
Lung Neoplasms (MeSH)
Advancements in Lung Cancer Research (OpenAlex Topic)
Small Cell Lung Cancer (OpenAlex Topic)
Role of Fibroblast Activation in Cancer Progression (OpenAlex Topic)
Author Keywords:
amivantamab
epidermal growth factor receptor
exon 20 insertion
non-small cell lung cancer
elink
Publication Type:
Article
Unique ID:
10.1016/j.lungcan.2023.02.008
PMID:
36868177
DOI:
10.1016/j.lungcan.2023.02.008
Journal:
Lung Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: